** IMPORTANT ANNOUNCEMENT **
Hello – thank you for your interest in the C-Path Data Archive. Please note that the PAN-TB, TB-APEX, and TB-PACTS data resources are currently being migrated from this platform to the C-Path Data Analytics Platform (CP-DAP). We are targeting late August 2025 for launch of these efforts within the CP-DAP.
If you are an existing PAN-TB, TB-APEX, and/or TB-PACTS C-Path Data Archive user, there will be a grace period where you will continue to have access to these data within the C-Path Data Archive through their retirement on this platform, currently slated for September 30th, 2025. Active users will be emailed with more detailed information regarding the next steps.
As we make this transition, there will be a moratorium placed on new applications for PAN-TB, TB-APEX, and TB-PACTS starting August 15th, 2025. We will begin to accept and process new applications within CP-DAP post-launch.
Thank you for your understanding and participation during this transition. We look forward to collaborating with you on this exciting next step for these efforts.
C-Path
Data Archive
The Critical Path Institute (C-Path) Data Archive is a unique resource for
researchers to aid in catalysing and accelerating drug and health research. The platform contains standardised
clinical trial and preclinical data which can be made available to qualified researchers.
This platform was made possible through funding from the Bill & Melinda Gates Foundation (BMGF) and is
currently being supported by funding from the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU).
For more information regarding C-Path, please visit c-path.org
Registered Users, login here
First time here?
If you have never applied for access to the Data Archive before, click below to see a list of databases to which you could apply for access.
C-PATH DATABASESThis project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853989. The JU receives support from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA and Global Alliance for TB Drug Development Non-Profit Organisation, Bill & Melinda Gates Foundation, University of Dundee
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101007873. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA, Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research.